Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections
Author(s) -
Nathaniel Warner,
Luther A. Bartelt,
Anne M. Lachiewicz,
Kathleen Tompkins,
Melissa B. Miller,
Kevin Alby,
Melissa B. Jones,
Amy Carr,
Jose Alexander,
Andrew B. Gainey,
Robert Daniels,
AnnaKathryn Burch,
David E. Brown,
Michael Brownstein,
Faiqa Cheema,
Kristin E. Linder,
Ryan K. Shields,
Sarah Longworth,
David van Duin
Publication year - 2020
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1847
Subject(s) - achromobacter xylosoxidans , cystic fibrosis , medicine , achromobacter , intensive care medicine , pseudomonas , bacteria , biology , genetics
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom